000			03020nam a22004455i 4500
001			85249
003			ES-MaUEC
005			20230207040502.0
007			cr nn 008mamaa
008			160315s2016 gw | s |||| 0|eng d
020			_a9783319268217
040			_aES-MaUEC
082	0	4	_a616.079
050		4	_aQR185.8.S96 _bE836 2016 EB
100	1		_aEscors, David _0Local _998057
245	1	0	_aMyeloid-Derived Suppressor Cells and Cancer _cby David Escors, James E Talmadge, Karine Breckpot, Jo A Van Ginderachter, Grazyna Kochan
250			_a1st ed.
264		1	_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (IX, 102 páginas) _b8 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aSpringerBriefs in Immunology _x2194-2773
505	0		_aControversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.
520			_aThe book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
710	2		_aSpringerLink (Online service) _0Local _9106996
830		0	_aMcGraw-Hill's AccessMedicine
942			_2lcc _cLE
988	0	0	_aEBOOK, EBSPRINGER
650		7	_aInmunología _0comprobar BNE19900958507 _2embne _9138330
700	1		_aTalmadge, James E. _998058 _0Local
700	1		_aBreckpot, Karine _0Local _998059
700	1		_aVan Ginderachter, Jo A. _998060 _0Local
700	1		_aKochan, Grazyna _0Local _998061
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-26821-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319268217
907			_a.b12945274 _b10-10-17 _c21-11-16
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1161349x _z30-06-17
998			_aSI _b07/2018 _cm _dz _ea _feng _gxxu _h0
999			_c85249 _d85249 _x1